- Home
- CDIO vs ACXP Comparison
CDIO vs ACXP Comparison
Compare CDIO & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- ACXP
- Stock Information
- Founded
- CDIO 2017
- ACXP 2017
- Country
- CDIO United States
- ACXP United States
- Employees
- CDIO N/A
- ACXP N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- CDIO Health Care
- ACXP Health Care
- Exchange
- CDIO Nasdaq
- ACXP Nasdaq
- Market Cap
- CDIO 8.0M
- ACXP 6.8M
- IPO Year
- CDIO N/A
- ACXP 2021
- Fundamental
- Price
- CDIO $4.23
- ACXP $6.80
- Analyst Decision
- CDIO
- ACXP Strong Buy
- Analyst Count
- CDIO 0
- ACXP 3
- Target Price
- CDIO N/A
- ACXP $143.67
- AVG Volume (30 Days)
- CDIO 47.5K
- ACXP 1.6M
- Earning Date
- CDIO 11-12-2025
- ACXP 11-12-2025
- Dividend Yield
- CDIO N/A
- ACXP N/A
- EPS Growth
- CDIO N/A
- ACXP N/A
- EPS
- CDIO N/A
- ACXP N/A
- Revenue
- CDIO $19,507.00
- ACXP N/A
- Revenue This Year
- CDIO $1,434.82
- ACXP N/A
- Revenue Next Year
- CDIO $4,661.91
- ACXP N/A
- P/E Ratio
- CDIO N/A
- ACXP N/A
- Revenue Growth
- CDIO N/A
- ACXP N/A
- 52 Week Low
- CDIO $3.22
- ACXP $3.80
- 52 Week High
- CDIO $53.10
- ACXP $41.00
- Technical
- Relative Strength Index (RSI)
- CDIO 50.58
- ACXP 63.75
- Support Level
- CDIO $4.03
- ACXP $6.75
- Resistance Level
- CDIO $4.66
- ACXP $7.98
- Average True Range (ATR)
- CDIO 0.35
- ACXP 0.70
- MACD
- CDIO -0.01
- ACXP 0.16
- Stochastic Oscillator
- CDIO 40.38
- ACXP 63.93
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.